Ivermectin In Treatment of COVID 19 Patients

Covid19 Clinical Trial

Official title:

The Use of Ivermectin In the Treatment of COVID 19 Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04425707
• Other study ID #: 14-2020/3
• Status: Recruiting
• Phase: N/A
• Start date: June 9, 2020
• Est. completion date: September 1, 2020

Study information

• Verified date: June 2020
• Source: Ministry of Health and Population, Egypt
• Contact: ehab ah kamal, MD
• Phone: 01006162663
• Email: ehabkamal2011[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Description:

the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 1, 2020
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

Exclusion Criteria:

• Contraindications for the drug: hypersensitivity.

• Any medications with possible drug interactions.

• Severe cases.

• Any malignant condition.

• Pregnant females.

• Breast feeding females.

• Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.

Related Conditions & MeSH terms

• Covid19

Intervention

Drug:
• Ivermectin
use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

Locations

Country	Name	City	State
Egypt	isolation and referal hospitals for COVID 19 patients	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ministry of Health and Population, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to evaluate the role of Ivermectin as a line of treatment for COVID 19	the role of ivermectin in the cure of COVID 19 patients	2 months
Secondary	To asses the rate of viral clearance in comparison to other treatment protocols.	to compare the results of ivermectin with the standard care	2 months